Tyzeka (Novartis Pharmaceuticals Corporation)
Welcome to the PulseAid listing for the Tyzeka drug offered from Novartis Pharmaceuticals Corporation. This Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Novartis Pharmaceuticals Corporation |
| NON-PROPRIETARY NAME: | telbivudine |
| SUBSTANCE NAME: | TELBIVUDINE |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] |
| ROUTE: | ORAL |
| DOSAGE FORM: | TABLET, FILM COATED |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2006-10-25 |
| END MARKETING DATE: | 2018-02-28 |
Tyzeka HUMAN PRESCRIPTION DRUG Details:
| Item Description | Tyzeka from Novartis Pharmaceuticals Corporation |
| LABELER NAME: | Novartis Pharmaceuticals Corporation |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 600(mg/1) |
| START MARKETING DATE: | 2006-10-25 |
| END MARKETING DATE: | 2018-02-28 |
| PRODUCT ID: | 0078-0538_55b54cf7-6c2f-4b87-a1db-94db34c17363 |
| PRODUCT NDC: | 0078-0538 |
| APPLICATION NUMBER: | NDA022011 |
Other TELBIVUDINE Pharmaceutical Manufacturers / Labelers:
